Roche CEO: Novel But Costly Gene Therapies Justify New Payment Models
Roche CEO Severin Schwan says the process of paying for hugely expensive gene therapies that can cure diseases needs revamping.
You may also be interested in...
Investors during Roche’s first-quarter update Wednesday will be looking for clues on looming biosimilar competition and timelines for the emergence of promising pipeline assets.
The Swiss major's proposed acquisition of Spark Therapeutics gives it a leading seat at the table in the emerging field of gene therapy.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.